RE:RE:ONCY P2 Bracelet-1 trial showed pelareorep as sole agentThe global Breast Cancer Market size is expected to be worth around USD 49.2 Bn by 2032 from USD 19.8 Bn in 2022
And with the potential use of pelareorep in combination with a checkpoint and CDK4/6 or PARP inhibitor, in 2L HR+/HER2- advanced or metastatic breast cancer, in which optimal second-line therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer is yet to be established, ONCYs acquisition valuation still remains in the multi-Billions.
Nothing has changed for ONCY other than pelareorep will be used as second line treatment in HR+/HER2- (or HER2 low) advanced or metastatic breast cancer , when combined with a CPI, plus possibly a CDK4/6 and PARP inhibitor, on the expected treatment relapes/failures/adverse effects on the anti-body drug conjugate (ADC) Enhertu.
https://www.enhertu.com/en/gastric/risks-and-side-effects